Rasagiline medical insurance prices

Rasagiline was tested for efficacy in patients with multiple system atrophy in a large randomized, placebo-controlled, double-blind disease-modified trial, but the drug failed and the clinical trial sought to prove that rasagiline not only treated symptoms but was a disease-modifying drug. It actually prevents the death of dopaminergic neurons that is characteristic of Parkinson's disease and slows the progression of the disease.

Rasagiline is a potent, selective and irreversible monoamine oxidase type B (MAO-B) inhibitor. Because it can prolong the action time of endogenous and exogenous dopamine, it can be used as a monotherapy or add-on drug to levodopa in patients with Parkinson's disease. For these reasons, rasagiline is considered a well-tolerated and effective drug both for the treatment of early-stage Parkinson's disease and for the dopaminergic treatment of Parkinson's disease patients with motor fluctuations.

The original drug of rasagiline has been launched in China and has entered the category of Class B medical insurance. The common name is rasagiline mesylate tablets, and the specifications areThe price of each box of 1mg*14 tablets may be around RMB 600. The price of the Turkish version of rasagiline's original drug, 1mg*30 tablets, per box sold overseas may be around RMB 310 (the price may fluctuate due to exchange rates). There are also generic drugs produced in other countries. The price of 1mg*100 tablets per box produced by Indian pharmaceutical factories may be around RMB 240 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs. For specific prices and drug information, please consult Yaode Medical Consultant.